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Abstract
Background: It is sometimes difficult to choose anti-thrombotic agents for secondary prevention in stroke patients
at high bleeding risk. Recently, Eicosapentaenoic Acid (EPA) was reported to reduce the recurrence of stroke in
hypercholesterolemic patients without increasing hemorrhagic risk. In this study, we investigated the features of
recurrent stroke patients during EPA medication as secondary stroke prevention.
Methods: Following the approval of the ethical committee, stroke patients in the outpatient clinic were
consecutively screened and patients who continuously take EPA were enrolled in this study (n = 71, average age
69.7 yo). Blood sample data was adopted from the latest visit or the admission at the stroke recurrence. According
to the previous stroke history, all patients were classified into the hemorrhagic stroke (HS) group (n = 10) and the
ischemic stroke, including asymptomatic infarction, (IS) group (n = 61).
Result: Any stroke recurrence was not observed in the HS group. Whereas, ischemic stroke recurrence was
observed in 6 patients in the IS group, although there was no hemorrhagic stroke recurrence. Recurrent stroke
patients showed the higher serum level of cholesterol or the renal dysfunction. The stroke subtype of patients
were 2 embolic strokes, 3 atherothrombotic infarctions (two were compromised with renal failure and one had
insufficient amount of EPA) and one lacunar infarction (who showed high triglyceride level).
Conclusion: Hemorrhagic stroke was not occurred in our observation of EPA prescribed patients. The clinical
features of recurrent stroke patients were the existing complications of dyslipidemia and renal dysfunction.
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Background
Eicosapentaenoic Acid (EPA) is one of essential fatty acid
and is contained mainly in fish oil. EPA has been reported
to not only reduce serum level of triglycerides and
low-density lipoprotein [1, 2], but also inhibit platelet
aggregation [3, 4] and reduce the arterial wall thickening
[5]. In the results of Japan EPA Lipid Intervention Study
(JELIS) sub-analysis, EPA could decrease the rate of stroke
recurrence without increasing the risk of hemorrhagic
incidence [6].
Meanwhile, as the medication for secondary stroke pre-
vention, anti-platelet agents are commonly prescribed [7].
However, some patients might suffer from recurrence of
ischemic stroke. Or, sometimes, intracerebral hemorrhage
(ICH) might occur on the ischemic stroke survivors who
are taking anti-thrombotics in higher rate compared
with patients without any anti-thrombotics [8]. Even,
hypertensive ICH patients sometimes have to take
anti-thrombotic agents, because they may have arterio-
sclerotic lesions. Therefore, it will become difficult to
choose anti-thrombotic agents for the patients, such as
ischemic stroke patients with high hemorrhagic risks
and ICH patients with severe arteriosclerotic lesions.
Of course, atherosclerotic risks are concurrently treated
with anti-thrombotic medications, and some medicines of
risk factor treatment, such as antihypertensive drugs
and lipid-lowering drugs, have been reported to show
the effect of stroke prevention [9].
In this context, EPA could be a candidate for the
additional anti-thrombotic agent. Since JELIS was a
large-scale cohort study, it is unclear that which type of
patients was appropriate or not appropriate for the use
of EPA as preventing stroke recurrence. Thus far, for
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being a help of discussing the optimal medication with
EPA, we revealed the clinical features of patients who were
suffered from stroke recurrence under EPA prescription.
Methods
Patients
Following the approval of the ethical committee of
Research Institute for Brain and Blood Vessels –Akita
(the document number is #14-20), stroke patients in the
outpatient clinic were consecutively screened during a
month of October 2013. Patients with a history of stroke
or patients with diagnosing asymptomatic brain infarction
and continuously prescribed EPA for more than one
month were enrolled in this study. Past history and medi-
cations were collected from clinical records. Vascular risk
factors were defined as follows: hypertension (>140 mmHg
of the systolic BP or >90 mmHg of the diastolic BP, or
currently prescribed anti-hypertensive drugs), diabetes
mellitus (casual blood glucose level >200 mg/dL or cur-
rently prescribed anti-diabetic medication), hyperlipidemia
(>220 mg/dL serum total cholesterol or >150 mg/dL
triglyceride, or currently prescribed anti-dyslipidemic
medication), alcohol drinking (>30 ml of alcohol conver-
sion amount per day) and smoking. Renal function was
assessed by calculating the estimated glomerular filtration
rate (eGFR), using the Japanese Society of Nephrology
formula [10]. Duration of EPA medication was calculated
in each patient. Stroke recurrence was set as the end
point. Blood sample data was adopted from the laboratory
examination of the latest visit or the admission at the
stroke recurrence. According to the previous stroke history,
all patients were classified into the hemorrhagic stroke
(HS) group (n = 10: patients with past ICH history) and the
ischemic stroke (IS) group (n = 61: patients with brain
infarction history, including asymptomatic infarction).
Statistical analysis
Data are presented as mean ± standard deviation (SD)
for continuous variables and percentage (%) for categorical
variables. To extract the features of recurrent stroke
patients, clinical backgrounds were compared between
asymptomatic patients, brain infarction (BI) with no
recurrent patients and BI with recurrent patients in the IS
group by the non-parametric one-way ANOVA test for
continuous variables and by the Pearson χ2 test for
categorical variables. All statistical analysis was performed
by JMP9 software (SAS Institute Inc., Cary, NC).
Results
As a total, 71 patients were enrolled in this study (male
44, female 27, average age: 69.7 ± 12.1 yo). The duration
of taking EPA was 14 years as maximum and 1 month
as minimum (average: 4.19 years). Clinical backgrounds
of all patients in the HS group were shown in Table 1.
There was no stroke recurrence in this group. Because
the number in each group was small, statistical analysis
was not applied. Clinical backgrounds of all patients in
the IS group was shown in Table 2. Although none of
hemorrhagic stroke was occurred, 6 ischemic stroke
recurrences were observed. These all recurrent cases
were not from the asymptomatic infarction but from
the BI patients. Then, the clinical characteristics were
compared between asymptomatic patients, no recurrent
patients (BI-no recurrence) and recurrent patients
(BI-recurrence). The level of serum triglyceride was
significantly higher in the BI-recurrence compared
with other groups (p = 0.046). The amount of serum
creatinine was significantly higher in the BI-recurrence
compared with other groups (p = 0.001). There was a sig-
nificant decline of eGFR in the BI-recurrence compared
with other groups (p = 0.008). Combination use of anti-
thrombotic agents was significantly in low frequency in
asymptomatic patients (p = 0.001).
Because the number of stroke recurrent patients was
small and the power of statistical analysis was weak, we
precisely observed all recurrent patients for revealing the
remarkable features in these patients. Two patients showed
the cardioembolic stroke. A 78 years-old woman was pre-
scribed EPA and a beta1 receptor blocker (metoprolol),
due to the asymptomatic brain infarction observed by a
Table 1 Clinical backgrounds of the HS group
ICH ICH + BI BI + ICH
N 6 2 2
Sex (F/M) 1/5 0/2 2/0
Age 63.5 ± 10.4 78.5 ± 9.2 71.0 ± 7.1
EPA (mg) 1950 ± 677 2288 ± 636 2372 ± 636
Length (years) 2.4 ± 1.0 5.1 ± 1.8 2.6 ± 0.6
Hypertension (%) 100 100 100
Hyperlipidemia (%) 83.3 50 100
DM (%) 16.7 0 100
Af (%) 16.7 0 0
TCho (mg/dl) 198.2 ± 21.5 157.0 ± 22.6 186.5 ± 57.3
LDL (mg/dl) 120.2 ± 18.6 87.0 ± 7.1 117.5 ± 57.3
TG (mg/dl) 89.5 ± 33.7 76.0 ± 18.4 100.0 ± 4.2
Cre (mg/dl) 0.7 ± 0.1 0.8 ± 0.1 0.7 ± 0.1
eGFR (ml/min/1.73 m2) 79.6 ± 11.9 76.2 ± 5.5 64.4 ± 16.1
AP, single (%) 0 0 50
AP, multi (%) 16.7 0 0
Warfarin (%) 16.7 0 0
W + AP (%) 0 50 0
None (%) 66.7 50 50
ICH intracranial hemorrhage, BI brain infarction, DM diabetes mellitus, Af atrial
fibrillation, T Cho total cholesterol, LDL low-density lipoprotein, TG triglyceride,
Cre creatinine, eGFR estimated Glomerular Filtration Rate, AP anti-platelet,
W warfarin
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health examination in 1 year and 7 months ago. She
had no atrial fibrillation history but had hypertension,
hyperlipidemia and diabetes mellitus as stroke risks.
Another woman was 70 years-old and was prescribed
EPA and an angiotensin II receptor blocker (ARB:
candesartan) for 2 years and 9 months. She had atrial
fibrillation and hyperlipidemia as stroke risks. She
had previous brain infarction 4 months ago. Other
three patients were the atherothrombotic infarction.
An 85 years-old man had atherothrombotic infarction
3 years ago and was prescribed EPA and an anti-platelet
agent (clopidogrel). He had hypertension and hyperlipid-
emia as stroke risks and showed the increased amount of
creatinine (1.4 mg/dl). A 91 years-old man had a history
of lacunar infarction and was prescribed EPA, aspirin,
clopidogrel, calcium channel blockers (CaB: benidipine
and nifedipine) and a dipeptidyl peptidase-4 inhibitor
(sitagliptin) for 4 years and 10 months. He had hyperten-
sion, hyperlipidemia and diabetes mellitus as stroke risks.
Moreover, he showed the increased amount of creatinine
(1.8 mg/dl). A 69 years-old woman had hyperlipidemia
and a history of cardioembolic infarction and was
prescribed EPA for 5 years and 9 months. However, the
prescribed dose of EPA (900 mg per day) was lower than
the recommended standard amount (1800 mg per day).
The last one patient was 66 years-old man. His stroke
subtype was the lacunar infarction. He had hypertension,
hyperlipidemia and diabetes mellitus as stroke risks. He
had a history of lacunar infarction two years ago, and was
started the prescription of EPA, an anti-platelet agent
(cilostazol), rosuvastatin, an ARB (valsartan) and a CaB
(amlodipine). Although he had taken EPA and statin, his
triglyceride amount was extremely high (911 mg/dl).
Discussion
This study clearly indicated the clinical features of the
recurrent ischemic stroke patients who were treated
with EPA as secondary stroke prevention. The recurrent
ischemic strokes had been accompanied by the compli-
cations of dyslipidemia or renal dysfunction, in spite of
EPA medication.
Actually, EPA is one of essential fatty acids and can be
purchased as a dietary supplement. However, the extra
purified EPA was developed as an anti-hyperlipidemia
agent and can be prescribed as an officially approved
medicine in Japan [11]. This concentrated EPA would
be suitable for assessing the medical effects in the
clinical situation. According to the observational study,
Greenlanders who had n-3 polyunsaturated fat rich diet
showed a reduced level of serum cholesterol and triglycer-
ide, resulting in a low incidence of acute myocardial
infarction [12, 13]. On the contrary, meta-analysis of
cohort studies revealed that there was no consistent
evidence of the reduction of cardiovascular events by
Table 2 Clinical backgrounds of the IS group
Asymptomatic BI-no recurrence BI-recurrence p value
N 13 42 6
Sex (F/M) 8/5 13/29 3/3 0.122
Age 72.1 ± 11.7 68.4 ± 12.7 76.5 ± 9.9 0.262
EPA (mg) 2077 ± 432 1907 ± 407 1650 ± 677 0.151
Length (years) 4.7 ± 4.2 3.9 ± 4.2 7.3 ± 5.4 0.200
Hypertension (%) 76.9 71.4 66.7 0.883
Hyperlipidemia (%) 83.3 85.0 100 0.500
DM (%) 75.0 42.9 33.3 0.191
Af (%) 7.7 9.5 16.6 0.824
TCho (mg/dl) 190.7 ± 46.8 170.3 ± 32.5 201.8 ± 28.2 0.054
LDL (mg/dl) 114.7 ± 39.7 96.9 ± 27.0 120.5 ± 43.2 0.088
TG (mg/dl) 140.8 ± 69.3 119.6 ± 53.5 248.5 ± 325.9 0.046
Cre (mg/dl) 0.7 ± 0.2 0.7 ± 0.2 1.1 ± 0.5 0.001
eGFR (ml/min/1.73 m2) 74.5 ± 18.8 85.0 ± 21.9 52.7 ± 23.3 0.008
AP, single (%) 7.7 45.2 50.0 0.041
AP, multi (%) 0 19.0 16.7 0.096
Warfarin (%) 7.7 7.1 0 0.536
W + AP (%) 0 4.8 0 0.490
None (%) 84.6 21.4 16.7 0.001
BI brain infarction, TCho total cholesterol, LDL low-density lipoprotein, TG triglyceride, Cre creatinine, eGFR estimated Glomerular Filtration Rate, AP anti-platelet,
W warfarin
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the omega-3 fats intake [14]. Meanwhile, JELIS trial
had showed that the incidence of major cardiovascular
events was significantly reduced in the hyperlipidemia
patients who treated with EPA addition to statin com-
pared with the hyperlipidemia patients who treated with
only statin [15]. In clinical situation, it was reported that
the serum level of adiponectin was significantly increased
by EPA administration in type 2 diabetic patients [16].
Metabolic syndrome patients treated with EPA showed a
significant reduction of small dense LDL and C-reactive
protein compared with those with diet alone [2]. JELIS
sub-analysis indicated that EPA prescription was more
effective for preventing the stroke recurrence than for
primary prevention of stroke. Moreover, there was no
increase of hemorrhagic incidence in the EPA treated
group compared with the control group [6]. Usually,
anti-platelet agents are prescribed for the prevention
of non cardioembolic stroke [7]. Even though, if a patient
taking aspirin or clopidogrel suffered from brain infarc-
tion as ischemic stroke recurrence, it might be puzzling
whether continuing current prescription or changing to
different medicine. In that situation, the additional
prescription of EPA can be expected to reduce the
risk of stroke recurrence without increasing the risk of
hemorrhagic complications. Therefore, to be a help of dis-
cussing the optimal medication with EPA as secondary
stroke prevention, we precisely described the features of
each recurrent stroke patients.
Originally, EPA has been reported to reduce the
amount of LDL and triglyceride [1, 2]. Moreover, the
intake of EPA could increase the EPA/arachidonic
acid (AA) ratio, leading to the positive regulation of
prostaglandin (PGI) and thromboxane (TXA) [4]. The
increase of EPA was reported to decrease the amount
of AA in platelet and reduce the TXA2 dependent
platelet aggregation [17]. According to our findings,
recurrent patients had significantly higher serum tri-
glyceride level compared with no recurrent patients.
One patient showed extremely high triglyceride level
in spite of taking EPA. Moreover, patients who had
stroke recurrence showed the increased amount of
serum creatinine and the decreased eGFR. The impaired
renal function, that is, chronic kidney disease (CKD) could
be a risk of stroke [18, 19]. Meanwhile, EPA could reduce
the oxidation of LDL and the lipid hydroperoxide
level in vitro, suggesting an anti-inflammatory effect
of EPA [20]. Therefore, the effect of EPA in patients
with CKD will be investigated in the future study.
Furthermore, there is a possibility of EPA for redu-
cing the risk of atrial fibrillation by enhancing the
vascular membrane stability. This effect might be
good for preventing embolic stroke indirectory. However,
we observed two embolic brain infarction as recurrent
stroke. It is another assignment to reduce the risk of
embolic stroke as stroke recurrence in patients with atrial
fibrillation.
Actually, because all data was retrospectively collected
from patient’s record, the prescribed EPA dose was not
standardized. Moreover, the duration of EPA medication
was diverted, i.e., from 1 month to 14 years. Then, the
recurrent cases were treated with EPA for from 4 month
to 5 years. When exploring the effect of EPA for reducing
stroke recurrence, the duration of treatment should be
considered. In the JELIS trial, the difference of the
accumulated recurrence rate between EPA treated and
non-EPA treated groups became prominent after 2 years.
Therefore, this study could not mention the results of the
effectiveness of EPA as secondary stroke prevention.
This study was a retrospective and the subjects were
only the patients who had continuously prescribed EPA
agent in our clinic. Therefore, there is a possibility of
overlooking the patients who had discontinued EPA
prescription after stroke recurrence or who had been
lost the follow up. Moreover, all data of the patients
were collected from outpatient clinic. It means that
there is a possibility in which patients might not take
EPA as the same as our prescription. It would be a
bias of influencing on the effect of EPA. However,
this situation could be experienced in usual practice.
Furthermore, since EPA can be contained in various
foods, especially fish oil, the serum EPA level may be
influenced by daily food intake. Considering the patients
in our study, all are from neighboring community and
their generation is close. That means they are assumed to
have similar daily foods. Therefore, although we had not
measured fatty acid fractionation in this study, it can
be considered that our data might not be affected by
patient’s diet. Even though taking these limitations into
consideration, our data could detect the clinical features
of recurrent stroke patients.
Conclusion
ICH as stroke recurrence was not observed in the patients
with EPA medication. In our observation, the recur-
rent ischemic stroke patients who had been taking
EPA showed the complications of dyslipidemia and renal
dysfunction.
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